Avesthagen IP model achieves valuation of Euro 115mn

Published on Sat, Jan 27, 2007 at 15:08 |  Source : Moneycontrol.com

Updated at Sat, Jan 27, 2007 at 16:49  

Like this story, share it with millions of investors on M3
0
0
Share on Tumblr

RELATED NEWS

Avestha Gengraine Technologies Pvt. Ltd. ("Avesthagen"), India's leading fully integrated life-sciences company, announces the successful closure of its Series 'C' fundraise totaling Euro 25 mn in equity investments, valuing the company at Euro 115 mn (approx. Rs. 667 crores).

 

The funds will be used for Avesthagen's infrastructure expansion plans, including setting up state-of-the-art manufacturing units, R&D laboratories, acquisition of technology companies in the domestic and overseas markets and furthering its international presence.

 

The investors in the series C round include Fidelity International, Limagrain group (France); Daninvest of Danone group (France) and Bennett Coleman (India). With this, total foreign investment in Avesthagen is now over 31%.  The new investors further strengthen the already robust existing investor base that includes ICICI Venture, Cipla, Godrej Industries, Tata Industries and bioMérieux. 

 

Ms. Renuka Ramnath, CEO & MD of ICICI Venture, commenting on the deal said: "ICICI Venture has always believed in the capability and potential of the Avesthagen business model.  We have partnered the company from the inception till date and are happy to see that under Villoo's leadership, it is all set to become a global player of repute."    

 

Contd on page 2....

  

More on Moneycontrol

Trending News

Business News

Tech2's Nokia Lumia Contest is Live
Forget the IIP: there's free cash oozing out of every pore "Forget the IIP: there's free cash oozing out of every pore "

DLF Says Macro Environment Unfavourable W/High Comm & Labour Inflation

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com